Vivriti Capital Limited
₹ 650▼6.47%(45.00)
About the company
Vivriti Capital Limited (VCL) is a leading mid-market lending and financial services company in India, dedicated to improving access to debt capital for businesses that are often underserved by traditional financing channels. The company focuses on supporting mid-sized enterprises across diverse sectors by offering customized financing solutions that help them expand operations, strengthen cash flows, and achieve long-term growth.
With a technology-driven approach and deep expertise in credit assessment, Vivriti Capital aims to bridge the funding gap for growing businesses while promoting greater financial inclusion in India's credit ecosystem. By combining data-driven underwriting with flexible lending solutions, the company enables enterprises to access timely and efficient capital. Committed to responsible lending, innovation, and sustainable growth, Vivriti Capital continues to play an important role in empowering India's mid-market businesses and contributing to the country's evolving financial landscape.
Fundamentals
Valuation
- 52 week high
- ₹1,050
- 52 week low
- ₹650
- P/B ratio
- 2.08
- ROE (%)
- 10.55%
- Book value
- ₹313.08
- Face value
- ₹10
- Valuation
- —
Registry
- ISIN number
- INE01HV01018
Figures in cr ·
Financials
| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| PAT | 1553 | -122 | 3.19 | 359 |
| EPS | 155.44 | -11.39 | 0.29 | 32.94 |
| Interest earned | 329 | 608 | 948 | 1286 |
| Other income | 2088 | 95 | 162 | 220 |
| Operating expenses | 121 | 131 | 208 | 242 |
| Provisions & contingencies | 15 | 09 | 103 | 194 |
| Gross NPA (%) | 0.29 | 0.31 | 1.09 | 1.89 |
| Net NPA (%) | 0.07 | 0.08 | 0.41 | 0.71 |
Shareholding Pattern
Leadership
Frequently asked questions
Common questions on Vivriti Capital Limited—tap a row to read the answer.
Q.1What does Vivriti Capital Limited do?
Vivriti Capital Limited is a financial services company that provides debt financing and structured credit solutions to India's mid-market businesses. The company focuses on helping enterprises that may have limited access to traditional sources of funding by offering customized lending solutions that support business expansion and long-term growth.
Q.2How can I buy Vivriti Capital Limited unlisted shares?
To invest in Vivriti Capital Limited unlisted shares, you need a valid PAN card and an active Demat account. Once the transaction is completed and the required documentation is verified, the shares are transferred electronically to your Demat account through an off-market transfer
Q.3What should investors evaluate before investing in Vivriti Capital Limited?
Before investing, consider factors such as the company's financial performance, loan portfolio quality, asset quality, business model, profitability, management team, funding strategy, valuation, and growth potential. Understanding these aspects can help investors make informed investment decisions.
Q.4What are the risks of investing in Vivriti Capital Limited unlisted shares?
Like any unlisted investment, Vivriti Capital Limited shares carry risks such as limited liquidity, price volatility, lower public disclosure compared to listed companies, and uncertainty regarding future listing plans. Investors should evaluate these risks alongside their investment objectives and risk tolerance.
Q.5Does Vivriti Capital Limited have any IPO plans?
As of now, there is no officially confirmed IPO launch date for Vivriti Capital Limited. If the company decides to pursue a public listing, updates are expected to be announced through official company communications and regulatory filings.
Trending shares
High-demand unlisted opportunities currently available for trade.
From the blog
Notes on unlisted markets, execution hygiene, and how we think about risk—no hype, no ticker spam.

APTUS PHARMA IPO
Aptus Pharma Limited rolled out its 100% book-built BSE SME public offering worth ₹13.02 Crore. Review crucial parameters for retail investors, featuring the ₹65–₹70 price band, working capital allocations, and an evaluation of its contract-manufacturing partner model.

NEPHROPLUS (NEPHROCARE HEALTH SERVICES) IPO
Explore the Neochem Bio IPO, including issue details, business strengths, risks, and investment analysis.

APOLLO TECHNO INDUSTRIES IPO
Apollo Techno Industries Limited has announced its public offering details. Explore the essential investment parameters for retail and institutional bidders, highlighting the fixed price band, lot structure, key market deadlines, and an overview of its industrial manufacturing footprint.

NEOCHEM BIO IPO
Explore the Neochem Bio IPO, including issue details, business strengths, risks, and investment analysis.

ANONDITA MEDICARE IPO
Anondita Medicare Limited rolled out its 100% book-built SME public offering worth ₹69.50 Crore on the NSE SME platform. Dig into the critical parameters for investors, highlighting the ₹137–₹145 price band, key working capital objectives, and an analysis of its flagship brand 'COBRA' within the growing sexual wellness market.

NEPTUNE LOGITEK IPO
Explore the Neptune Logitek IPO, including issue details, business strengths, risks, and investment analysis.
